Improved prognosis for biomarkers in breast cancer
Author:
- 1 June 1998
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 351 (9118) , 1753-1754
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.Journal of Clinical Oncology, 1998
- Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with responseBreast Cancer Research and Treatment, 1998
- bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.Journal of Clinical Oncology, 1997
- Preoperative chemotherapy induces apoptosis in early breast cancerThe Lancet, 1997
- The important prognostic value of Ki-67 expression as determined by image analysis in breast cancerJournal of Cancer Research and Clinical Oncology, 1996
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996
- Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapyBreast Cancer Research and Treatment, 1994
- Prognostic Factors and Therapeutic Decisions in Axillary Node-Negative Breast CancerAnnual Review of Medicine, 1993
- The Nottingham prognostic index in primary breast cancerBreast Cancer Research and Treatment, 1992
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992